- Home
- VRA vs SKYE Comparison
VRA vs SKYE Comparison
Compare VRA & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRA
- SKYE
- Stock Information
- Founded
- VRA 1982
- SKYE 2012
- Country
- VRA United States
- SKYE United States
- Employees
- VRA N/A
- SKYE N/A
- Industry
- VRA Apparel
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- VRA Consumer Discretionary
- SKYE Health Care
- Exchange
- VRA Nasdaq
- SKYE Nasdaq
- Market Cap
- VRA 94.8M
- SKYE 80.7M
- IPO Year
- VRA 2010
- SKYE N/A
- Fundamental
- Price
- VRA $3.22
- SKYE $2.98
- Analyst Decision
- VRA Strong Buy
- SKYE Buy
- Analyst Count
- VRA 1
- SKYE 6
- Target Price
- VRA $5.50
- SKYE $18.67
- AVG Volume (30 Days)
- VRA 200.6K
- SKYE 223.9K
- Earning Date
- VRA 03-12-2025
- SKYE 02-25-2025
- Dividend Yield
- VRA N/A
- SKYE N/A
- EPS Growth
- VRA N/A
- SKYE N/A
- EPS
- VRA N/A
- SKYE N/A
- Revenue
- VRA $405,268,000.00
- SKYE N/A
- Revenue This Year
- VRA N/A
- SKYE N/A
- Revenue Next Year
- VRA $4.90
- SKYE N/A
- P/E Ratio
- VRA N/A
- SKYE N/A
- Revenue Growth
- VRA N/A
- SKYE N/A
- 52 Week Low
- VRA $3.14
- SKYE $2.31
- 52 Week High
- VRA $8.32
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- VRA 36.44
- SKYE 48.34
- Support Level
- VRA $3.14
- SKYE $2.97
- Resistance Level
- VRA $3.52
- SKYE $3.31
- Average True Range (ATR)
- VRA 0.16
- SKYE 0.37
- MACD
- VRA -0.00
- SKYE 0.01
- Stochastic Oscillator
- VRA 13.33
- SKYE 40.00
About VRA Vera Bradley Inc.
Vera Bradley Inc designs women's handbags, travel items, and accessories. Each category comprises a substantial component of total sales, with the bags category comprising the most. most of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The majority of revenue is from the Vera Bradley Direct segment.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.